NUVL Stock Analysis: Buy, Sell, or Hold?
NUVL - Nuvalent, Inc. Class A Common Stock
$105.43
-0.21 (-0.20%)
▼
5d:
+7.52%
30d:
+2.69%
90d:
+4.81%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When NUVL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NUVL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NUVL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NUVL is currently trading at $105.43, which is considered extended relative to its 30-day fair value range of $97.16 to $103.25.
Technical Outlook: Technically, NUVL is in a downtrend. The price is approaching resistance at $106.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUVL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $142.39 (+35.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NUVL is in a downtrend. The price is approaching resistance at $106.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUVL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $142.39 (+35.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$97.16 -
$103.25
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.1% below Wall St target ($142.39)
Fair Price Analysis
30-Day Fair Range
$97.16 -
$103.25
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$93.91
Resistance Level
$106.90
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.13
Wall Street Target
$142.39
(+35.1%)
Share & Embed Analysis
Last updated: April 02, 2026 6:57 PM ET
Data refreshes hourly during market hours. Next update: 7:57 PM
Data refreshes hourly during market hours. Next update: 7:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUVL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Deborah Ann Miller
SELL
14300 shares
2026-01-22
Deborah Ann Miller
SELL
700 shares
2026-01-21
Alexandra Balcom
SELL
3181 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
